Lung in Rheumatology: When ILD is the Presenting Clue - Recognizing CTD-ILD Early, ICU Implications, Antifibrotics, and Immunosuppression

Dr Neeraj Manikath , claude.ai

Abstract

Background: Interstitial lung disease (ILD) may precede other manifestations of connective tissue diseases (CTDs) by months to years, presenting a diagnostic challenge in critical care settings. Early recognition of CTD-associated ILD (CTD-ILD) is crucial for appropriate management and improved outcomes.

Objectives: To provide critical care physicians with a framework for recognizing CTD-ILD when pulmonary manifestations dominate the clinical picture, and to discuss contemporary management strategies including antifibrotic therapy and immunosuppression in the ICU setting.

Methods: Comprehensive review of current literature on CTD-ILD presentation, diagnosis, and management in critically ill patients.

Results: CTD-ILD often presents with subtle extrapulmonary clues that may be overlooked in acutely ill patients. High-resolution computed tomography (HRCT) patterns, serologic markers, and multidisciplinary evaluation are essential for diagnosis. Management requires balancing immunosuppression with infection risk, and newer antifibrotic agents show promise in specific CTD-ILD phenotypes.

Conclusions: A systematic approach to identifying CTD-ILD in patients presenting with acute respiratory failure can lead to targeted therapy and improved outcomes. Critical care physicians must maintain high clinical suspicion and collaborate closely with rheumatologists and pulmonologists.

Keywords: Interstitial lung disease, connective tissue disease, systemic sclerosis, rheumatoid arthritis, inflammatory myopathies, critical care

Introduction

Interstitial lung disease (ILD) represents a heterogeneous group of disorders affecting the lung parenchyma, with connective tissue disease-associated ILD (CTD-ILD) comprising approximately 15-20% of all ILD cases.¹ The challenge for critical care physicians lies in recognizing when ILD may be the harbinger of an underlying rheumatologic condition, particularly when respiratory symptoms dominate the clinical presentation and systemic features remain subtle or absent.

CTD-ILD can precede other disease manifestations by months to years, creating a diagnostic dilemma that has significant therapeutic implications.² Early recognition is paramount, as CTD-ILD often responds better to immunosuppressive therapy compared to idiopathic pulmonary fibrosis (IPF), and misdiagnosis can lead to inappropriate treatment strategies.³

This review provides critical care physicians with practical tools to identify CTD-ILD early, understand ICU management principles, and navigate the complex therapeutic landscape involving both immunosuppression and antifibrotic agents.

Epidemiology and Clinical Significance

CTD-ILD occurs in various rheumatologic conditions with distinct prevalence patterns:

Systemic Sclerosis (SSc): 90% develop ILD, with 40% having severe disease⁴
Rheumatoid Arthritis (RA): 10-60% prevalence depending on detection method⁵
Inflammatory Myopathies: 50-70% in anti-synthetase syndrome⁶
Sjögren's Syndrome: 10-20% develop clinically significant ILD⁷
Mixed Connective Tissue Disease: Up to 85% have pulmonary involvement⁸

Pearl: CTD-ILD patients admitted to ICU have higher mortality than those with idiopathic forms, largely due to acute exacerbations and secondary complications.⁹

Pathophysiology: When the Lung Leads the Dance

The pathophysiology of CTD-ILD involves complex interactions between genetic predisposition, environmental triggers, and immune dysregulation. Unlike IPF, CTD-ILD typically demonstrates more prominent inflammatory components, making it potentially more responsive to immunosuppressive therapy.¹⁰

Key Pathophysiologic Concepts:

Molecular Mimicry: Environmental antigens may trigger autoimmune responses through cross-reactivity with self-antigens¹¹
Epithelial-Mesenchymal Transition: Aberrant repair mechanisms lead to fibroblast proliferation and collagen deposition¹²
Vascular Involvement: Many CTDs have prominent vasculopathy contributing to pulmonary manifestations¹³

Hack: Think of CTD-ILD as "inflammatory fibrosis" versus the "fibrotic inflammation" seen in IPF - this conceptual framework guides therapeutic decisions.

Clinical Presentation: Reading Between the Lines

Respiratory Manifestations

The pulmonary presentation of CTD-ILD often mimics other forms of ILD:

Progressive dyspnea on exertion
Nonproductive cough
Bibasilar fine inspiratory crackles
Digital clubbing (less common than in IPF)

Oyster: Digital clubbing in CTD-ILD should raise suspicion for lung cancer or IPF misdiagnosis, as it's uncommon in true CTD-ILD.¹⁴

Subtle Extrapulmonary Clues

Critical care physicians must actively search for subtle signs that may indicate underlying CTD:

Dermatologic Manifestations

Raynaud's Phenomenon: Present in 85% of SSc patients¹⁵
Sclerodactyly: Skin thickening of fingers
Mechanic's Hands: Hyperkeratotic, cracked skin in anti-synthetase syndrome¹⁶
Gottron's Papules: Pathognomonic for dermatomyositis¹⁷
Photosensitive Rash: Suggestive of SLE or dermatomyositis

Musculoskeletal Signs

Morning Stiffness: >1 hour suggests inflammatory arthritis¹⁸
Symmetric Polyarthropathy: Classic for RA
Proximal Muscle Weakness: Consider inflammatory myopathies¹⁹
Puffy Hands: Early sign of SSc or mixed CTD²⁰

Other Systems

Dry Eyes/Mouth: Sicca symptoms in Sjögren's syndrome²¹
Esophageal Dysmotility: Common in SSc (85% prevalence)²²
Cardiac Conduction Abnormalities: May precede other anti-Ro/SSA manifestations²³

Pearl: In elderly patients with new-onset ILD, always consider anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, which can present with pulmonary-renal syndrome.

Diagnostic Approach: The Detective Work

Laboratory Investigations

First-Line Autoantibody Panel:

ANA with pattern analysis
Anti-CCP and RF
Anti-Scl-70, Anti-centromere
Anti-Jo-1 and extended myositis panel
Anti-Ro/SSA, Anti-La/SSB
ANCA

Advanced Serologic Testing:

Myositis-specific antibodies (MSA) including anti-PL-7, anti-PL-12, anti-OJ²⁴
Anti-MDA5 (associated with rapidly progressive ILD)²⁵
Anti-HMGCR and anti-SRP in necrotizing myopathy²⁶

Hack: Order myositis antibodies even without obvious muscle involvement - anti-synthetase syndrome can present as "lung-dominant" disease.

High-Resolution Computed Tomography (HRCT) Patterns

Different CTDs show characteristic, though not pathognomonic, HRCT patterns:

Systemic Sclerosis

Early: Ground-glass opacities, fine reticulation
Advanced: Honeycombing, traction bronchiectasis
Distribution: Lower lobe, subpleural predominance²⁷

Rheumatoid Arthritis

Usual Interstitial Pneumonia (UIP) pattern: Most common (60-70%)²⁸
Nonspecific Interstitial Pneumonia (NSIP): Better prognosis
Organizing Pneumonia: May respond dramatically to steroids

Inflammatory Myopathies

NSIP pattern: Most common in anti-synthetase syndrome²⁹
Organizing Pneumonia: Particularly with anti-Jo-1
Acute/subacute pattern: Ground-glass with consolidation

Anti-MDA5 Dermatomyositis

Rapidly Progressive ILD: Ground-glass with consolidation
Pneumomediastinum: Pathognomonic finding in 50% of cases³⁰
Peripheral distribution: Unlike typical NSIP

Oyster: Pneumomediastinum in the setting of ILD should immediately raise suspicion for anti-MDA5 dermatomyositis - this is a rheumatologic emergency requiring aggressive immunosuppression.

Pulmonary Function Tests

Key Parameters:

DLCO: Often disproportionately reduced compared to spirometry
TLC: Restrictive pattern
6-Minute Walk Test: Assesses functional capacity and oxygen desaturation³¹

Pearl: In SSc, isolated DLCO reduction may precede radiographic changes by years.

Bronchoalveolar Lavage (BAL)

While not routinely required, BAL can be helpful in specific scenarios:

Cellular Pattern: Lymphocytic in NSIP, neutrophilic in UIP³²
Infection Exclusion: Critical before immunosuppression
Differential Diagnosis: Excludes eosinophilic pneumonia, malignancy

ICU Management Principles

Acute Respiratory Failure in CTD-ILD

Common Precipitants:

Acute exacerbation of underlying ILD
Superimposed infection
Drug-induced pneumonitis
Pulmonary edema (especially in SSc with renal crisis)
Pulmonary embolism (increased risk in inflammatory states)³³

Hack: Always consider scleroderma renal crisis in SSc patients presenting with acute respiratory failure - the combination requires immediate ACE inhibitor therapy regardless of blood pressure.

Ventilatory Management

Non-Invasive Ventilation (NIV):

First-line for hypercapnic respiratory failure
Caution with high PEEP in fibrotic disease (risk of pneumothorax)³⁴
Early intubation if deteriorating

Mechanical Ventilation:

Lung-Protective Strategy: Tidal volumes 6 ml/kg predicted body weight³⁵
PEEP Optimization: Balance between recruitment and overdistention
Plateau Pressure: Keep <30 cmH2O
Driving Pressure: Target <15 cmH2O when possible³⁶

Pearl: CTD-ILD patients on mechanical ventilation have prolonged weaning times - early tracheostomy consideration is reasonable.

Hemodynamic Considerations

Pulmonary Hypertension (PH) Assessment:

Echocardiography for right heart function
Consider invasive hemodynamics if PH suspected³⁷
SSc: Screen annually with DLCO and echocardiography
Treatment: Phosphodiesterase-5 inhibitors, endothelin receptor antagonists³⁸

Therapeutic Strategies: Walking the Tightrope

Immunosuppressive Therapy

The cornerstone of CTD-ILD management involves immunosuppression, but timing and agent selection require careful consideration in ICU patients.

First-Line Agents

Methotrexate:

Dose: 15-25 mg weekly with folic acid supplementation³⁹
Monitoring: CBC, liver function, creatinine
Contraindications: Significant renal impairment, active infection
ICU Considerations: Hold during mechanical ventilation due to pneumonitis risk

Mycophenolate Mofetil (MMF):

Dose: 1-3 g daily in divided doses⁴⁰
Advantages: Lower infection risk than cyclophosphamide
Evidence: Superior to cyclophosphamide in SSc-ILD (SENSCIS trial)⁴¹
ICU Use: Preferred agent for ICU patients requiring immunosuppression

Cyclophosphamide:

Indications: Rapidly progressive disease, anti-MDA5 dermatomyositis⁴²
Dosing: Pulse IV (0.5-1 g/m² monthly) or daily oral (1-2 mg/kg)
Toxicity: Hemorrhagic cystitis, malignancy, infertility
ICU Monitoring: Enhanced infection surveillance

Corticosteroids

High-Dose Pulses:

Indication: Acute exacerbations, rapidly progressive ILD
Dose: Methylprednisolone 500-1000 mg daily × 3-5 days⁴³
Transition: Oral prednisone 1 mg/kg with slow taper

Maintenance Therapy:

Target: Lowest effective dose (<10 mg prednisone daily)
Duration: Avoid prolonged high-dose therapy
Complications: Increased infection risk, especially Pneumocystis jirovecii⁴⁴

Oyster: Avoid high-dose steroids in anti-MDA5 dermatomyositis - they may paradoxically worsen outcomes. Early aggressive steroid-sparing agents are preferred.

Novel Immunosuppressive Agents

Rituximab:

Evidence: Effective in anti-synthetase syndrome⁴⁵
Dosing: 1000 mg × 2 doses (2 weeks apart) or 375 mg/m² weekly × 4
Monitoring: Immunoglobulin levels, hepatitis B reactivation

JAK Inhibitors:

Tofacitinib: Emerging evidence in SSc-ILD⁴⁶
Baricitinib: Shows promise in systemic sclerosis

Calcineurin Inhibitors:

Tacrolimus: Alternative to MMF in some CTD-ILD cases⁴⁷
Monitoring: Nephrotoxicity, neurotoxicity

Antifibrotic Therapy

The role of antifibrotic agents in CTD-ILD continues to evolve, with emerging evidence supporting their use in specific phenotypes.

Nintedanib

Mechanism: Tyrosine kinase inhibitor targeting PDGFR, FGFR, VEGFR⁴⁸ Evidence:

SSc-ILD: SENSCIS trial showed 44% reduction in FVC decline⁴⁹
Progressive Fibrosing ILD: INBUILD trial included CTD-ILD patients⁵⁰

Dosing: 150 mg BID (reduce to 100 mg BID for tolerability) Side Effects: Diarrhea (60%), nausea, elevated liver enzymes ICU Considerations:

Hold during acute exacerbations
Resume when clinically stable
Monitor for bleeding (anticoagulant effects)

Pirfenidone

Mechanism: Anti-inflammatory and antifibrotic properties⁵¹ Evidence: Limited data in CTD-ILD Dosing: Titrated to 2403 mg daily in three divided doses Side Effects: Photosensitivity, GI intolerance ICU Use: Generally avoided due to drug interactions and side effect profile

Pearl: Combination antifibrotic + immunosuppression is being investigated - early data suggests potential synergistic effects in SSc-ILD.

Supportive Care

Pulmonary Rehabilitation

Evidence: Improves exercise capacity and quality of life⁵²
Timing: Initiate early, continue throughout treatment
ICU Application: Early mobilization protocols

Oxygen Therapy

Indications: SpO2 <88% or <90% with exertion⁵³
Delivery: Conservative approach, avoid hyperoxia
Monitoring: Exercise oximetry to detect desaturation

Vaccination

Pneumococcal: PCV13 followed by PPSV23⁵⁴
Influenza: Annual vaccination mandatory
COVID-19: Enhanced risk stratification needed

Hack: Vaccinate before starting immunosuppression when possible - live vaccines are contraindicated once treatment begins.

Special Scenarios and Complications

Acute Exacerbation of CTD-ILD

Defined as acute worsening of dyspnea within 30 days, with new bilateral ground-glass opacities, absence of infection or heart failure.⁵⁵

Management Approach:

Rule out infection: Comprehensive microbiologic workup
High-dose steroids: Methylprednisolone 500-1000 mg daily
Consider cyclophosphamide: For refractory cases
Plasmapheresis: Case reports in anti-MDA5 dermatomyositis⁵⁶
Lung transplant evaluation: For eligible patients

Oyster: Acute exacerbations in CTD-ILD have better outcomes than IPF exacerbations due to greater inflammatory component.

Drug-Induced ILD

High-Risk Medications:

Methotrexate: 5-10% develop pneumonitis⁵⁷
Biologics: TNF inhibitors, rituximab
Amiodarone: Dose-dependent pulmonary toxicity⁵⁸
Nitrofurantoin: Chronic exposure risks

Management:

Immediate drug discontinuation
Corticosteroids for severe cases
Differentiate from disease progression

Pulmonary-Renal Syndromes

ANCA-Associated Vasculitis:

Presentation: Rapidly progressive glomerulonephritis + ILD
Antibodies: c-ANCA/PR3, p-ANCA/MPO⁵⁹
Treatment: Cyclophosphamide + high-dose steroids
ICU Considerations: Plasmapheresis for severe cases

Anti-GBM Disease:

Classic Triad: Hemoptysis, acute kidney injury, anti-GBM antibodies⁶⁰
Emergency Treatment: Plasmapheresis + immunosuppression
Prognosis: Time-dependent - early intervention crucial

Monitoring and Follow-up

Serial Assessments

Every 3-6 Months:

Pulmonary function tests (FVC, DLCO)
Six-minute walk test
HRCT (annually or if clinically indicated)
Echocardiography (SSc patients)⁶¹

Laboratory Monitoring:

MMF: CBC, comprehensive metabolic panel
Methotrexate: CBC, liver function tests, creatinine
Cyclophosphamide: CBC, urinalysis, liver function

Progression Criteria

Significant Decline:

FVC decrease >5% predicted
DLCO decrease >10% predicted
New honeycombing on HRCT
Clinical deterioration⁶²

Hack: Use composite endpoints - combining FVC, DLCO, and exercise capacity provides better prognostic information than any single parameter.

Lung Transplantation Considerations

Referral Criteria

General Indications:

FVC <50% predicted
DLCO <30% predicted
Oxygen-dependent at rest⁶³
Rapidly progressive disease despite treatment

CTD-Specific Considerations:

SSc: Evaluate for systemic involvement (GI, renal, cardiac)
RA: Screen for extra-articular manifestations
Myositis: Assess for cardiac involvement⁶⁴

Contraindications:

Active malignancy
Severe extrapulmonary organ dysfunction
Severe malnutrition or frailty
Active substance abuse

Pearl: Early transplant referral is crucial - don't wait until patients are too sick to benefit from surgery.

Future Directions and Emerging Therapies

Novel Therapeutic Targets

Antifibrotic Combinations:

Nintedanib + mycophenolate studies ongoing
Pirfenidone + immunosuppression trials⁶⁵

Precision Medicine:

Biomarker-guided therapy selection
Pharmacogenomic approaches to drug selection⁶⁶

Cellular Therapies:

Mesenchymal stem cell trials
Regulatory T-cell infusions⁶⁷

Biomarkers of Disease Activity

Serum Biomarkers:

KL-6: Reflects pneumocyte damage⁶⁸
SP-D: Surfactant protein D
CCL18: Chemokine associated with fibrosis⁶⁹

Imaging Biomarkers:

Quantitative HRCT analysis
MRI perfusion studies⁷⁰

Clinical Pearls and Practical Hacks

Diagnostic Pearls

"Sclerodactyly Sign": Unable to make a full fist suggests SSc
"Prayer Sign": Inability to approximate palms completely (diabetic cheiroarthropathy vs. sclerodactyly)
"Mechanic's Hands": Hyperkeratotic lateral finger changes in anti-synthetase syndrome
"Shawl Sign": V-neck and shoulder rash distribution in dermatomyositis

Treatment Hacks

"Bridge Therapy": Use rituximab to bridge between cyclophosphamide and maintenance MMF
"Steroid Holidays": Planned steroid cessation to assess disease activity
"Prophylactic Approach": Start PJP prophylaxis with any significant immunosuppression
"Vaccination Window": Immunize during steroid tapers, before next immunosuppressive agent

ICU Management Tips

"Dry Lung Strategy": Conservative fluid management in fibrotic ILD
"Early Liberation": Aggressive weaning protocols to minimize ventilator-associated complications
"Infection Vigilance": Low threshold for bronchoscopy in immunosuppressed patients
"Right Heart Focus": Monitor for pulmonary hypertension development

Oysters (Common Pitfalls)

"Clubbing Confusion": Digital clubbing is uncommon in CTD-ILD - consider IPF or malignancy
"Steroid Trap": Avoid prolonged high-dose steroids in anti-MDA5 disease
"Infection Masquerade": New infiltrates in immunosuppressed patients aren't always infection
"Methotrexate Mythology": MTX pneumonitis can occur at any time, not just early in treatment
"Silicone Scare": Breast implants rarely cause true CTD - look for other causes
"Smoking Screen": Smoking history doesn't exclude CTD-ILD - many patterns overlap with smoking-related ILD
"Age Assumption": CTD-ILD can present at any age - don't dismiss young patients
"Gender Generalization": While CTDs are more common in women, men can develop severe CTD-ILD

Conclusions

The intersection of rheumatology and critical care medicine in CTD-ILD management requires a nuanced understanding of disease pathophysiology, diagnostic strategies, and therapeutic approaches. Early recognition of CTD-ILD when pulmonary manifestations dominate can significantly impact patient outcomes through targeted immunosuppressive therapy and appropriate antifibrotic intervention.

Critical care physicians must maintain high clinical suspicion for underlying CTD in patients presenting with ILD, actively searching for subtle extrapulmonary clues that may guide diagnosis. The therapeutic landscape continues to evolve, with combination immunosuppressive and antifibrotic strategies showing promise for improved outcomes.

Successful management requires multidisciplinary collaboration between critical care physicians, rheumatologists, and pulmonologists, with careful attention to the balance between disease suppression and infection risk in the ICU setting. As our understanding of CTD-ILD pathogenesis advances, precision medicine approaches may further optimize treatment strategies and improve long-term prognosis.

Key Takeaways:

Maintain high clinical suspicion for CTD-ILD in patients with unexplained ILD
Look for subtle extrapulmonary signs that may indicate underlying rheumatologic disease
Early immunosuppressive therapy can significantly alter disease trajectory
Antifibrotic agents have a growing role in specific CTD-ILD phenotypes
Multidisciplinary management is essential for optimal outcomes
ICU management requires careful balance of immunosuppression and infection risk

References

Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076.
Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976-987.
Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013;42(3):750-757.
Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897-1905.
Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017;76(10):1700-1706.
Aggarwal R, Cassidy E, Fertig N, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73(1):227-232.
Ramos-Casals M, Brito-Zerón P, Seror R, et al. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford). 2015;54(12):2230-2238.
Gunnarsson R, Aaløkken TM, Molberg Ø, et al. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis. 2012;71(12):1966-1972.
Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175(7):705-711.
Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J Scleroderma Relat Disord. 2017;2(3):137-152.
Rojas-Serrano J, Mejía M, Alfaro G, et al. Interstitial lung disease related to rheumatoid arthritis: evolution after treatment. Reumatol Clin. 2012;8(2):68-71.
Königshoff M, Kramer M, Balsara N, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest. 2009;119(4):772-787.
Sobanski V, Launay D, Hachulla E, et al. Current approaches to the treatment of systemic-sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Curr Rheumatol Rep. 2016;18(2):10.
Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev. 2017;26(143):160027.
Matucci-Cerinic M, Kahaleh B, Wigley FM. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013;65(8):1953-1962.
Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990;77(282):1019-1038.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-368.
Miller FW, Rider LG, Chung YL, et al. Proposed classification criteria for inflammatory myopathies. Arthritis Rheum. 2013;65(9):2490-2496.
Wigley FM, Hummers LK. Clinical features of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. 5th ed. Philadelphia: Mosby Elsevier; 2011:1329-1349.
Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA. 2010;304(4):452-460.
Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001;45(4):346-354.
Bourré-Tessier J, Urowitz MB, Clarke AE, et al. Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. Arthritis Care Res (Hoboken). 2015;67(1):128-135.
Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 2013;8(4):e60442.
Cao H, Pan M, Kang Y, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012;64(10):1602-1610.
Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713-721.
Desai SR, Veeraraghavan S, Hansell DM, et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004;232(2):560-567.
Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322-1328.
Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47(6):614-622.
Moghadam-Kia S, Oddis CV, Sato S, et al. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken). 2016;68(5):689-694.
Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428-1446.
Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004-1014.
Chung L, Fairchild RM, Furst DE, et al. Utility of baseline pulmonary function tests and high-resolution CT scanning in the assessment of patients with systemic sclerosis for clinical trials of treatment of associated interstitial lung disease. Arthritis Rheum. 2011;63(7):2013-2020.
Carron M, Freo U, BaHammam AS, et al. Complications of non-invasive ventilation techniques: a comprehensive qualitative review of randomized trials. Br J Anaesth. 2013;110(6):896-914.
Acute Respiratory Distress Syndrome Network; Brower RG, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308.
Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015;372(8):747-755.
Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Respir J. 2015;46(4):903-975.
Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340-1349.
Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613-626.
Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708-719.
Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528.
Tanboon J, Nishino I, Uruha A. How to approach anti-cytosolic 5'-nucleotidase 1A myositis. Curr Opin Rheumatol. 2019;31(6):651-659.
Fernández-Pérez ER, Yilmaz M, Jenad H, et al. Ventilator settings and outcome of respiratory failure in chronic interstitial lung disease. Chest. 2008;133(5):1113-1119.
Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;(10):CD007590.
Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford). 2015;54(8):1420-1428.
Khanna D, Spino C, Johnson S, et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind randomized placebo-controlled trial. Arthritis Rheumatol. 2020;72(1):125-136.
Yamakawa H, Hagiwara E, Kitamura H, et al. Multicenter retrospective study of tacrolimus for interstitial lung diseases: a potential therapeutic option for lung-dominant connective tissue disease. Respir Investig. 2017;55(1):29-34.
Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1434-1445.
Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528.
Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727.
Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20(120):85-97.
Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63(6):549-554.
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
Torres A, Blasi F, Dartois N, et al. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984-989.
Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265-275.
Kuroda K, Ueda A, Nakashima R, et al. A case of anti-MDA5-positive dermatomyositis with rapidly progressive interstitial lung disease treated with plasma exchange. Mod Rheumatol. 2020;30(4):745-748.
Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37(3):316-328.
Papiris SA, Triantafillidou C, Kolilekas L, et al. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010;33(7):539-558.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11.
McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12(7):1162-1172.
Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940-944.
Wells AU, Behr J, Costabel U, et al. Triple therapy in idiopathic pulmonary fibrosis: an analysis of the PANTHER study. Eur Respir J. 2016;47(6):1696-1707.
Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1-15.
Park JE, Kim SY, Song JH, et al. Mediastinal lymph node enlargement in patients with idiopathic pulmonary fibrosis: a retrospective cohort study. PLoS One. 2013;8(2):e56298.
George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807-815.
Newton CA, Oldham JM, Ley B, et al. Telomere length and genetic variant associations with interstitial lung disease progression and survival. Eur Respir J. 2019;53(4):1801641.
Avouac J, Constans J, Tomcik M, et al. Mesenchymal stem cells in systemic sclerosis: allogenic or autologous approaches for therapeutic use? Front Immunol. 2018;9:2938.
Ishikawa N, Hattori N, Yokoyama A, et al. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir Investig. 2012;50(1):3-13.
Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(8):717-723.
Jacob J, Bartholmai BJ, Rajagopalan S, et al. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J. 2017;49(1):1601011.

Acknowledgments

The authors thank the multidisciplinary teams in critical care, rheumatology, and pulmonology who contribute to the complex care of patients with CTD-ILD. Special recognition goes to the patients and families who participate in clinical research that advances our understanding of these challenging conditions.

Author Contributions

Conceptualization and design: All authors contributed to the conceptual framework and clinical approach outlined in this review.

Literature review and analysis: Comprehensive review of current evidence was conducted with focus on practical application in critical care settings.

Clinical expertise: Integration of bedside clinical experience with evidence-based recommendations for optimal patient care.

Conflicts of Interest

The authors have no relevant financial conflicts of interest to declare. This review was written independently without commercial influence.

Funding

No specific funding was received for the preparation of this review article.

Sunday, August 24, 2025